The latest news from the Indian pharma industry, including WHO’s recommendation not to use cough syrup from Marion Biotech after further deaths, Indegene’s expanded presence in Europe, Sun Pharma’s FDA warning and the lab partnership between Sai Life Sciences and Schrödinger.


WHO recommends not using Marion Biotech cough syrups linked to Uzbekistan deaths (Reuters)

The World Health Organization (WHO) has said that two cough syrups made by India’s Marion Biotech should not be used for children after the products were linked to 19 deaths in Uzbekistan. Analysis by Uzbekistan’s health ministry showed the syrups, Ambronol and DOK-1 Max, contained the toxic substance ethylene glycol.


India’s Union Budget 2023-24: Impact on healthcare infrastructure and pharma (The Times of India)

The Indian pharmaceutical industry, according to this analysis, expects an expansion in the government’s budget outlay and fund allocations in this year’s Union Budget, the annual budget of the Republic of India to be presented in February. The healthcare sector saw a 16 percent hike in last year’s budget allocation due to the pandemic.


Indegene expands presence in Europe with new center in Germany (BioSpectrum Asia)

Indegene, an Indian digital-first, life sciences commercialization company, has set up a new centre in Germany. The firm says it will use this centre to accelerate the digital transformation of life sciences companies in Europe. Indegene already has a significant presence in the region, with centers in the UK, Ireland, and Switzerland.


H.B. Fuller to launch new Bio-Compatible medical adhesive (BioSpectrum Asia)

India-headquartered adhesives supplier H.B. Fuller has announced the launch of Swift®melt 1515-I, its first bio-compatible product for medical tape applications. According to the company, the new medical tape has excellent adhesion, is easy to remove and has been certified by ISO 10993-5.


Sun Pharma facility gets warning from the FDA (Endpoints)

A Sun Pharma manufacturing sites has been given a warning letter from the FDA after it was placed on an import alert. The FDA’s letter involves a 23-page Form 483 inspection in April and May of last year after an inspection revealed several violations, including the generics maker not accurately simulating commercial operations and “poor aseptic techniques.”


Sai Life Sciences partners with Schrödinger on research lab in India (Endpoints)

Indian contract research and manufacturing company, Sai Life Sciences, has signed a 5-year agreement with Schrödinger to set up a research laboratory on Sai’s R&D campus in Hyderabad. The lab, for which Schrödinger will provide technological platforms, will be dedicated to researching medicinal and synthetic chemistry, in vitro biology and other chemical processes to develop candidates.